Teva Pharmaceutical Industries Ltd. (TEVA)

6.41
0.25 4.06
NYSE : Health Technology
Prev Close 6.16
Open 6.21
Day Low/High 6.08 / 6.44
52 Wk Low/High 6.07 / 25.96
Volume 17.78M
Avg Volume 19.98M
Exchange NYSE
Shares Outstanding 1.09B
Market Cap 6.75B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

More Generic Mergers Ahead?

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

PFE was ready to pay $160 billion until U.S. regulators blocked the deal.

The Oracle of Omaha Is Off His Game

The Oracle of Omaha Is Off His Game

Be careful backing Buffett right now, his biggest holdings show increasing profit pressure.

Jim Cramer: This Is Now an Emotional Market

Jim Cramer: This Is Now an Emotional Market

When traders are flailing and investors are drowning, examples work best to illustrate what happens before a bottom is reached.

It Happens to the Best of Us!

If you get down on yourself in some of your trades and investments - check out the 2-3 year chart on Teva Pharmaceuticals . And consider that The Oracle of Omaha, Warren Buffett, owns over 43 million shares. I have been negative on fundamental groun...

How Low Can Teva Pharmaceutical Stock Go? Don't Fight the Tape

How Low Can Teva Pharmaceutical Stock Go? Don't Fight the Tape

Do not try to pick a bottom on this stock.

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

But is a Teva turnaround still coming after the stock's 70% loss in the past five years?

More Mud on Johnson & Johnson?

More Mud on Johnson & Johnson?

There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.

Upgrades, Downgrades, New Research

Before I jump on the radio, here's a quick list of upgrades, downgrades and new research coverage coming out of Wall Street this morning... - Hilltop Holdings upgraded to Overweight from Neutral at Piper Jaffray - Trex upgraded to Buy from Hold at S...

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Market Direction, Big Anniversary and a GE Play: Market Recon

Market Direction, Big Anniversary and a GE Play: Market Recon

There is still no news on China trade, so keep your chinstrap buckled and wear your flak jacket.

S&P 500 Is Testing Resistance, and How to Play Activision: Market Recon

S&P 500 Is Testing Resistance, and How to Play Activision: Market Recon

China trade discussions will continue to be a key driver in Wednesday's market action.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

I See No Technical Reason to Approach Teva Pharmaceuticals From the Long Side

I See No Technical Reason to Approach Teva Pharmaceuticals From the Long Side

Jim Cramer was bearish on TEVA.

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.

Eli Lilly Shares Decline on Tuesday Despite Strong Earnings Release

Eli Lilly Shares Decline on Tuesday Despite Strong Earnings Release

Eli Lilly's excellent earnings weren't excellent enough.

Eli Lilly Offers Healthy Outlook to Kick Off November

Eli Lilly Offers Healthy Outlook to Kick Off November

The giant drugmaker raised its profit guidance for all of 2018 after its third-quarter results beat expectations.

Markets Are Headed For a More Difficult Environment: Market Recon

Markets Are Headed For a More Difficult Environment: Market Recon

Santa is on his way... A lot of pressure on the jolly fellow this year.

Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It

Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It

For equity holders in Amarin, now's the time to be implementing my 'Jensen Rules.'

How I See Biotechs Now

How I See Biotechs Now

I expect deal volume to have a substantial uptick before the end of 2018 rolls around.

Retailers Offering Safe Havens

"Despite a voluminous and often fervent literature on "income distribution," the cold fact is that most income is not distributed: It is earned."  -- Thomas Sowell Markets are pretty much trading at the same levels as our last update as it looks lik...

Five-Day Winning Streak in Stocks Expected to Continue

Five-Day Winning Streak in Stocks Expected to Continue

On Thursday alone, we experience both free-fall, as well as a raucous rally.

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

We used to think of what's in the public's interest when it comes to securities.

Clearly, Warren Buffett Loves Apple's Stock

Clearly, Warren Buffett Loves Apple's Stock

Warren Buffett continues to eat up Apple's stock. He also has bought a stake in struggling generics drug maker Teva.

What's Behind the Hound of Hades' Stock Market Rampage

What's Behind the Hound of Hades' Stock Market Rampage

The free market is going to take back control of interest rates.